Condition
Pituitary Dwarfism
Total Trials
4
Recruiting
0
Active
0
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
50%
2 trials in Phase 3/4
Results Transparency
25%
1 of 4 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
2Total
P 3 (2)
Trial Status
Completed4
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT01009905Completed
An Observational Study (Registry) Assessing Treatment Outcomes and Safety for Children and Adults Who Are Prescribed Norditropin® (Human Growth Hormone)
NCT00102817Phase 3Completed
Somatropin (Norditropin) in Insulin-like Growth Factor (IGF) Deficient Children
NCT01504802CompletedPrimary
Pharmacodynamics of CNP During Growth Hormone Treatment
NCT00109733Phase 3Completed
Cool.Click™ Adolescent Transition Study: Study of Saizen® in Subjects With Childhood-onset Growth Hormone Deficiency
Showing all 4 trials